News
Displaying 1–10 of 525
-
Opus Genetics Receives FDA Clearance to Launch Clinical Trial for Best1 Gene Therapy
Research NewsThe Foundation funded earlier, proof-of-concept studies for the Best1 gene therapy and later launched Opus to develop several IRD gene therapies.
-
jCyte Launches New Phase 2 Clinical Trial for its Cell-Based RP Therapy
Research NewsThe trial is evaluating a cell dose that is 50 percent higher than the highest dose used in a previous Phase 2b trial.
-
Wet AMD Treatment Susvimo Preserves Vision for Five Years in Phase 3 Clinical Trial
Research NewsSusvimo is an FDA-approved treatment that continuously delivers drug through a tiny, implanted capsule
-
Ocugen Launches Phase 2/3 Clinical Trial for Stargardt Disease Gene-Modifier Therapy
Research NewsThe therapy delivers copies of the RORA gene to address multiple disease pathways.
-
Nanoscope Begins Rolling BLA Submission to FDA for Seeking Approval for its Optogenetic Therapy
Research NewsThe company plans to complete BLA submission in early 2026.
-
Atsena Gets FDA Nod to Expand XLRS Gene Therapy Clinical Trial to Include Pivotal Phase 3 Cohort
Research NewsThe expanded Phase 1/2/3 shortens time to potential FDA approval.
-
Retinitis Pigmentosa Research Advances
Research NewsRecent developments in research on retinitis pigmentosa.
-
Stargardt Disease Research Advances
Research NewsRecent developments in research on Stargardt disease.
-
Leber Congenital Amaurosis Research Advances
Research NewsRecent developments in research on Leber congenital amaurosis.
-
Age-Related Macular Degeneration Research Advances
Research NewsRecent developments in research on age-related macular degeneration.
